C-IDDApartial reprogramming, senolytic polyphenols, longevity diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
199 Biotechnologies partial reprogramming, senolytic polyphenols, longevity diagnostics
199 Biotechnologies builds therapies that address cancer and aging through epigenetic damage and cellular reprogramming. Its lead program is E-ON-001, a preclinical cancer reprogramming therapy focused on glioblastoma. The company also develops senolytic polyphenol compounds and the AgeQuant diagnostic platform for lower-cost biomarker testing.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
199 Biotechnologies — Early mechanism · Bottom quartile. Derived deterministically from 6 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic